PH-762 is under clinical development by Phio Pharmaceuticals and currently in Phase I for Cutaneous Squamous Cell Carcinoma (cSCC). According to GlobalData, Phase I drugs for Cutaneous Squamous Cell Carcinoma (cSCC) have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PH-762’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PH-762 overview
PH-762 is under development for the treatment of solid tumors, melanoma, ovarian cancer, colon cancer, head and neck squamous cell cancer, Merkel Cell Carcinoma, hepatocellular carcinoma, metastatic melanoma and cutaneous Squamous Cell Carcinoma. It comprises tumor infiltrating lymphocytes modified with sd-rxRNAi (self-deliverable RNAi). It is administered through intratumorally and through subcutaneous route The drug candidate acts by targeting programmed cell death protein 1(PD1). It is developed based INTASYL therapeutic platform.
It was also under development for the treatment of triple-negative breast cancer.
Phio Pharmaceuticals overview
Phio Pharmaceuticals, formerly known as RXi Pharmaceuticals, is a biotechnology company. The company’s pipeline products include PH-762 for the treatment of stages I, II, and IV cutaneous squamous cell carcinoma (c SCC), stage IV melanoma, and stage IV merkel cell carcinoma; PH-894 is for the treatment of stage IV melanoma, head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), human papillomavirus (HPV) related cutaneous squamous cell carcinoma (c SCC). It also provides clinical trial services. The company partners with academia, biotech and large multi-national organizations for the development of new therapeutics. Phio Pharmaceuticals is headquartered in Marlborough, Massachusetts, the US.
For a complete picture of PH-762’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
